Head-To-Head Analysis: PotNetwork (POTN) & OpGen (OPGN)

OpGen (NASDAQ:OPGN) and PotNetwork (OTCMKTS:POTN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Institutional and Insider Ownership

7.2% of OpGen shares are held by institutional investors. Comparatively, 0.0% of PotNetwork shares are held by institutional investors. 7.1% of OpGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


This table compares OpGen and PotNetwork’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OpGen -453.73% -232.38% -119.08%
PotNetwork N/A N/A N/A

Volatility & Risk

OpGen has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, PotNetwork has a beta of 3.25, indicating that its share price is 225% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for OpGen and PotNetwork, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OpGen 0 0 2 0 3.00
PotNetwork 0 0 0 0 N/A

OpGen currently has a consensus target price of $4.15, indicating a potential upside of 713.73%. Given OpGen’s higher possible upside, research analysts plainly believe OpGen is more favorable than PotNetwork.

Earnings and Valuation

This table compares OpGen and PotNetwork’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OpGen $2.95 million 1.49 -$13.37 million ($2.22) -0.23
PotNetwork N/A N/A N/A N/A N/A

PotNetwork has lower revenue, but higher earnings than OpGen.


OpGen beats PotNetwork on 5 of the 9 factors compared between the two stocks.

About OpGen

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

About PotNetwork

PotNetwork Holdings, Inc, through its subsidiary, First Capital Venture Co., engages in the research, development, and sale of hemp-derived CBD oil products. It also engages in the pre-owned auto dealership business. The company sells its products through distributors and resellers, as well as through its Website. The company was formerly known as SND Auto Group Inc. and changed its name to PotNetwork Holdings, Inc in March 2017. PotNetwork Holdings, Inc is based in Fort Lauderdale, Florida.

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.